Genepharm into its Strides
Friday, 13 June, 2008
Shareholders in Australian generic medicines company Genepharm (ASX: GAA) will vote next week on a $61 million plan to acquire the Australian and Asian operating arms of Strides Arcolab, an Indian-based manufacturer of gelatine capsules for pharmaceutical dosage.
The acquisitions are expected to generate up to $32.5 million in sales in 2006/2007, with an EBITDA of around $7.4 million.
In exchange for the trade of Strides regional businesses, Genepharm will give Strides a stake of up to 40 per cent of the company. This will bring Strides' shareholding in Genepharm to up to 55 per cent.
Genepharm said ownership of the businesses would allow it instant access to markets throughout southeast Asia.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
